Good Health Can’t Wait.

More documents

Recommendations

Info

Good Health Can’t Wait. Dr. Reddy’s Laboratories Limited All amounts in Indian Rupees millions, except share data and where otherwise stated AS AT 31 MARCH 2015 FOR THE YEAR ENDED 31 MARCH 2015 SL. NO. NAME OF THE SUBSIDIARY REPORTING PERIOD FOR THE SUBSIDIARY % OF SHAREHOLDING REPORTING CURRENCY EXCHANGE RATE SHARE CAPITAL RESERVES & SURPLUS OTHER LIABILITIES TOTAL EQUITY AND LIABILITIES TOTAL ASSETS INVESTMENTS (EXCL. INVESTMENT IN SUBSIDIARIES) TURNOVER PROFIT/(LOSS) BEFORE TAXATION PROVISION FOR TAXATION PROFIT/(LOSS) AFTER TAXATION PROPOSED DIVIDEND 25 Dr. Reddy’s New Zealand Limited 31.03.2015 100% NZD 46.76 - 33 30 63 63 - 92 (38) 8 (46) - 26 Dr. Reddy’s Pharma SEZ Limited 31.03.2015 100% INR 1.00 1 (1) - - - - - - - - - 27 Dr. Reddy’s Singapore PTE. Limited 31.03.2015 100% SGD 45.48 25 6 9 40 40 - 48 7 - 7 - 28 Dr. Reddy’s Srl 31.03.2015 100% EUR 67.19 6 (804) 838 40 40 - 84 37 - 37 - 29 Dr. Reddy's Venezuela, C.A. 31.03.2015 100% VEF 9.92 (4) 58 443 3,500 4,001 4,001 - 8,126 1,189 710 479 - 30 DRL Impex Limited 31.03.2015 100% INR 1.00 1 (740) 759 20 20 - - (57) 3 (60) - 31 Euro Bridge Consulting B.V. 31.03.2015 100% EUR 67.19 37 111 5 153 153 - - (1) - (1) - 32 Idea2Enterprises (India) Private Limited 31.03.2015 100% INR 1.00 24 1,422 4 1,450 1,450 - - - - - - 33 Industrias Quimicas Falcon de Mexico, S.A. de C.V. 31.03.2015 100% MXN 4.10 594 (537) 4,541 4,598 4,598 - 4,875 441 184 257 - 34 I-Ven Pharma Capital Limited (till 20 November 2014) (5) 31.03.2015 100% INR 1.00 - - - - - - - - - - - 35 Kunshan Rotam Reddy Pharmaceutical Company Limited 31.03.2015 51.33% RMB 10.08 791 864 809 2,464 2,464 - 3,358 488 67 421 - 36 Lacock Holdings Limited 31.03.2015 100% EUR 67.19 1 150 21 172 172 - - 22 3 19 - 37 OctoPlus Development B.V. (3) 31.03.2015 100% EUR 67.19 1 1,400 271 1,672 1,672 - 1,521 540 - 540 - 38 OctoPlus B.V. (3) 31.03.2015 100% EUR 67.19 451 602 2,048 3,101 3,101 - - (30) 1 (31) - 39 OctoPlus PolyActive Sciences B.V. (3) 31.03.2015 100% EUR 67.19 1 - - 1 1 - - - - - - 40 OctoPlus Sciences B.V. (3) 31.03.2015 100% EUR 67.19 1 67 - 68 68 - - (23) - (23) - 41 OctoPlus Technologies B.V. (3) 31.03.2015 100% EUR 67.19 1 (3,078) 3,084 7 7 - - (330) - (330) - 42 OctoShare B.V. (3) 31.03.2015 100% EUR 67.19 2 741 107 850 850 - - (173) - (173) - 43 OOO Dr. Reddy's Laboratories Limited 31.03.2015 100% RUB 1.07 72 1,852 7,304 9,228 9,228 - 17,430 1,241 170 1,071 - 44 OOO DRS LLC 31.03.2015 100% RUB 1.07 30 104 90 224 224 - - 39 - 39 - 45 Promius Pharma LLC (1) 31.03.2015 100% USD 62.50 1,713 (6,712) 7,009 2,010 2,010 - 653 (2,198) - (2,198) - 46 Reddy Antilles N.V. 31.03.2015 100% USD 62.50 52 (173) 340 219 219 - - (24) - (24) - 47 Reddy Cheminor S.A. (under liquidation) 31.03.2015 100% EUR 67.19 2 (2) - - - - - - - - - 48 Reddy Holding GmbH (2) 31.03.2015 100% EUR 67.19 2 13,258 12,826 26,086 26,086 - - 7,143 482 6,661 - 49 Reddy Specialities GmbH (2) 31.03.2015 100% EUR 67.19 2 - - 2 2 - - - - - - 50 Reddy Netherlands B.V. 31.03.2015 100% EUR 67.19 7 3,789 54 3,850 3,850 - - (416) 1 (417) - 51 Reddy Pharma Iberia SA 31.03.2015 100% EUR 67.19 566 (520) 2 48 48 - 20 17 - 17 - 52 Reddy Pharma Italia S.p.A 31.03.2015 100% EUR 67.19 63 (140) 1,059 982 982 - - (7) - (7) - (1) Tax expense for these entities is computed together as per the tax laws of United States. The total tax expense is presented in Sl. No. 16 - Dr. Reddy’s Laboratories Inc. (2) Tax expense for these entities is computed together as per the tax laws of Germany. The total tax expense is presented in Sl. No. 48 - Reddy Holding GmbH. (3) Tax expense for these entities is computed together as per the tax laws of Netherlands. The total tax expense is presented in Sl. No. 38 - OctoPlus B.V. (4) 9.92 INR per VEF is derived from the CENCOEX rate of VEF 6.3 per USD. The Company has used SIMADI rate of VEF 193 per USD in the Consolidated Financial Statements for translating certain monetary assets and liabilities of its Venezuelan subsidiary which may not be eligible for the CENCOEX rate of VEF 6.3 per USD. (5) During the year, I-Ven Pharma Capital Limited, a wholly owned subsidiary of the company was liquidated. 90
Statutory Reports • Board’s Report Annual Report 2014 - 15 PART “B”: ASSOCIATES AND JOINT VENTURES SL. NO. NAME OF THE ASSOCIATES AND JOINT VENTURES LATEST AUDITED BALANCE SHEET DATE SHARES OF ASSOCIATE/ JOINT VENTURES HELD BY THE COMPANY ON THE YEAR END NO. AMOUNT OF INVESTMENT IN ASSOCIATES/ JOINT VENTURE EXTEND OF HOLDING % NET WORTH ATTRIBUTABLE TO SHAREHOLDING AS PER LATEST AUDITED BALANCE SHEET PROFIT/LOSS FOR THE YEAR CONSIDERED IN CONSOLIDATION NOT CONSIDERED IN CONSOLIDATION DESCRIPTION OF HOW THERE IS A SIGNIFICANT INFLUENCE REASON WHY THE ASSOCIATE/JOINT VENTURE IS NOT CONSOLIDATED 1 DRANU LLC, USA NA NA 360 50% 43 (125) – NA NA 2 DRSS Solar Power Private Limited, India (1) 31.03.2015 26,000 – 26% – – – NA NA (1) DRSS Solar Power Private Limited, India is yet to commence operations. for and on behalf of the Board of Directors of Dr. Reddy’s Laboratories Limited K Satish Reddy Chairman G V Prasad Co-Chairman & Chief Executive Officer Place Hyderabad Saumen Chakraborty President & Chief Financial Officer Date 12 May 2015 Sandeep Poddar Company Secretary ANNEXURE - II FORM NO. AOC–2 (Pursuant to clause (h) of sub-section (3) of Section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014) Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of Section 188 of the Companies Act, 2013 including certain arm’s length transactions under third proviso thereto Details of contracts or arrangements or transactions not at arm’s length basis : None (a) (b) (c) (d) (e) (f) (g) (h) Name(s) of the related party and nature of relationship Nature of contracts/arrangements/transactions Duration of the contracts/arrangements/transactions Salient terms of the contracts or arrangements or transactions including the value, if any Justification for entering into such contracts or arrangements or transactions Date(s) of approval by the Board Amount paid as advances, if any Date on which the special resolution was passed in general meeting as required under first proviso to Section 188 Not Applicable Details of material contracts or arrangement or transactions at arm’s length basis (a) Names(s) of the related party and nature of relationship Dr. Reddy’s Laboratories Inc., USA- Wholly-owned subsidiary (b) Nature of contracts/arrangements/transactions Transfer or receipt of products, goods, materials or services. (c) Duration of the contracts/arrangements transactions Ongoing. (d) Salient terms of the contracts or arrangements or transactions including the value, if any: Transfer or receipt of products, goods, materials or services on arm’s length for an estimated amount of up to US$ 1,100 million every financial year. (e) Date(s) of approval by the Board, if any 13 May 2014 (f) Amount paid as advances, if any – K Satish Reddy Chairman 91
Page 1 and 2:
ANNUAL REPORT 2014-15 Good Health C
Page 3 and 4:
Our Brand We are in the business of
Page 5 and 6:
Corporate Overview Annual Report 20
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Statutory Reports • Business Resp
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42: Statutory Reports • Business Resp
Page 43 and 44: Statutory Reports • Management Di
Page 57 and 58: Statutory Reports • Corporate Gov
Page 73 and 74: Statutory Reports • Additional Sh
Page 87 and 88: Statutory Reports • Board’s Rep
Page 91: Statutory Reports • Board’s Rep
Page 111 and 112: Standalone Financial Statements Ann
Page 143 and 144:
Standalone Financial Statements Ann
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Consolidated Financial Statements A
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Notice Annual Report 2014 - 15 NOTI
Page 229 and 230:
E-Voting Annual Report 2014 - 15 IN
Page 231:
Dr. Reddy’s Laboratories Limited
Page 235 and 236:
The future belongs, not to those wh
show all

Good Health Can’t Wait.

Create successful ePaper yourself

Delete template?

Save as template?